6589 fundamentals
Key facts
Market capitalization—
Founded—
CEO—
Website—
About
EirGenix, Inc. engages in the research and development of biotechnology drugs. Its products and services include Trastuzumab Biosimilar, Pertuzumab Biosimilar, New Formulation, Antibody-Drug Conjugate, Bevacizumab Biosimilar, CRM197 Carrier Protein, and Biosimilar. The company was founded by Li Cheng Liu on December 21, 2012 and is headquartered in New Taipei, Taiwan.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
Dividends
Dividend yield, history and sustainability
No dividends
6589 has never paid dividends and has no current plans to do so.
Financial health
Financial position and solvency of the company